基本信息
浏览量:110
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
She is also an Associate Director for the Institute of Personalized Medicine | Pharmacogenomics U of M Alliance (PUMA-IPM) and a member of the Masonic Cancer Center at the University of Minnesota. She is a member of American Association for Cancer Research (AACR), American Society of Human Genetics (ASHG), and American Society of Clinical Pharmacology and Therapeutics (ASCPT). To date, she has published over 80 original research papers many of which are in high caliber journals, e.g., Nature, Nature Medicine, PNAS, Blood, Cancer Research, Genome Biology and American Journal of Human Genetics. Dr. Huang is a board certified clinical pharmacologist with extensive training in genetics, molecular and cell biology, clinical trials and high throughput data analysis.
The Huang laboratory’s main research focus is translational pharmacogenomics with particular interest in the pharmacogenomics of anti-cancer agents. By systematically evaluating human genome and its relationships to drug response and toxicity, their goal is to develop clinically useful models that predict risks for adverse drug reactions and non-response prior to administration of chemotherapy. With her broad training background, Dr. Huang assembles and leads a multi-disciplinary team that consists of computational biologist, geneticist, pharmacist, physician, molecular biologist and biostatistician to tackle a series of serious problems in cancer research. These include the lack of mechanistic understanding of genomic regulation of cancer phenotypes; the lack of reproducible predictive biomarkers for cancer therapeutic agents; and the lack of effective treatment for many hard to treat cancers. More information about the Huang lab can be found online at http://huang-lab.umn.edu/
The Huang laboratory’s main research focus is translational pharmacogenomics with particular interest in the pharmacogenomics of anti-cancer agents. By systematically evaluating human genome and its relationships to drug response and toxicity, their goal is to develop clinically useful models that predict risks for adverse drug reactions and non-response prior to administration of chemotherapy. With her broad training background, Dr. Huang assembles and leads a multi-disciplinary team that consists of computational biologist, geneticist, pharmacist, physician, molecular biologist and biostatistician to tackle a series of serious problems in cancer research. These include the lack of mechanistic understanding of genomic regulation of cancer phenotypes; the lack of reproducible predictive biomarkers for cancer therapeutic agents; and the lack of effective treatment for many hard to treat cancers. More information about the Huang lab can be found online at http://huang-lab.umn.edu/
研究兴趣
论文共 208 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ARCHIVES OF TOXICOLOGYno. 4 (2024): 1191-1208
Archives of toxicologyno. 4 (2024): 1191-1208
Cancer Researchno. 6_Supplement (2024): 6205-6205
Weijie Zhang,Danielle Maeser,Adam Lee,Yingbo Huang,Robert F Gruener, Israa G Abdelbar,Sampreeti Jena,Anand G Patel,R Stephanie Huang
CURRENT OPINION IN STRUCTURAL BIOLOGY (2024): 102745-102745
Mitesh L. Rathod,Wen Yih Aw,Stephanie Huang,Jingming Lu,Elizabeth L. Doherty, Chloe P. Whithworth, Gang Xi,Prabir Roy-Chaudhury,William J. Polacheck
SMALLno. 24 (2024): e2307901-e2307901
Journal of Clinical Oncologyno. 16_suppl (2024): 2082-2082
Expert opinion on drug discoverypp.1-13, (2024)
Pharmaceuticals (Basel, Switzerland)no. 5 (2024): 569
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn